肝细胞性肝癌(Hepatocellularcarcinoma,HCC)是世界性恶性肿瘤,近二十年来由于早期诊断技术的发展和以手术切除为主的综合治疗模式的建立,HCC术后5年生存率已超过45%,其中小肝癌5年生存率提高到60%～70%,但患者长期预后不容乐观,经根治性手术2年后近半数HCC复发,即便是小肝癌5 Hepatocellular carcinoma (HCC) is a worldwide malignant tumor. Over the past two decades, the early 5-year survival rate of HCC has exceeded 45% due to the development of early diagnostic techniques and the establishment of a comprehensive treatment model based on surgical resection. The 5-year survival rate of small hepatocellular carcinoma was increased to 60%-70%, but the long-term prognosis of the patients was not optimistic. After radical surgery for 2 years, nearly half of the HCC recurred, even small hepatocellular carcinoma 5